Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.81
PDLI's Cash-to-Debt is ranked lower than
82% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. PDLI: 0.81 )
Ranked among companies with meaningful Cash-to-Debt only.
PDLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 0.84 Max: No Debt
Current: 0.81
Equity-to-Asset 0.62
PDLI's Equity-to-Asset is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PDLI: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
PDLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.93  Med: 0.47 Max: 0.98
Current: 0.62
-1.93
0.98
Interest Coverage 15.82
PDLI's Interest Coverage is ranked lower than
84% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 15.82 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 4.85  Med: 14 Max: 20.34
Current: 15.82
4.85
20.34
Piotroski F-Score: 3
Altman Z-Score: 2.83
Beneish M-Score: -3.08
WACC vs ROIC
5.97%
24.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 83.91
PDLI's Operating Margin % is ranked higher than
99% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. PDLI: 83.91 )
Ranked among companies with meaningful Operating Margin % only.
PDLI' s Operating Margin % Range Over the Past 10 Years
Min: 61.19  Med: 93.26 Max: 94.93
Current: 83.91
61.19
94.93
Net Margin % 49.04
PDLI's Net Margin % is ranked higher than
96% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. PDLI: 49.04 )
Ranked among companies with meaningful Net Margin % only.
PDLI' s Net Margin % Range Over the Past 10 Years
Min: -69.4  Med: 55.26 Max: 59.61
Current: 49.04
-69.4
59.61
ROE % 24.77
PDLI's ROE % is ranked higher than
94% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. PDLI: 24.77 )
Ranked among companies with meaningful ROE % only.
PDLI' s ROE % Range Over the Past 10 Years
Min: -26.17  Med: 72.89 Max: 1166.18
Current: 24.77
-26.17
1166.18
ROA % 16.29
PDLI's ROA % is ranked higher than
94% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. PDLI: 16.29 )
Ranked among companies with meaningful ROA % only.
PDLI' s ROA % Range Over the Past 10 Years
Min: -11.28  Med: 38.22 Max: 77.05
Current: 16.29
-11.28
77.05
ROC (Joel Greenblatt) % 418.00
PDLI's ROC (Joel Greenblatt) % is ranked higher than
97% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. PDLI: 418.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 50.13  Med: 2574.8 Max: 673588.24
Current: 418
50.13
673588.24
3-Year Revenue Growth Rate 11.50
PDLI's 3-Year Revenue Growth Rate is ranked higher than
63% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PDLI: 11.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.9  Med: 14.7 Max: 43.7
Current: 11.5
4.9
43.7
3-Year EBITDA Growth Rate 11.80
PDLI's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. PDLI: 11.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.2  Med: 13.1 Max: 433.7
Current: 11.8
-17.2
433.7
3-Year EPS without NRI Growth Rate 11.90
PDLI's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. PDLI: 11.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -89.5  Med: 11.3 Max: 798.3
Current: 11.9
-89.5
798.3
GuruFocus has detected 4 Warning Signs with PDL BioPharma Inc $PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PDLI's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PDLI Guru Trades in Q1 2016

Jeremy Grantham 2,457,115 sh (+1149.17%)
Jim Simons 12,724,354 sh (+22.99%)
Barrow, Hanley, Mewhinney & Strauss 298,243 sh (+5.86%)
First Eagle Investment 2,800 sh (unchged)
Joel Greenblatt 3,732,679 sh (-21.40%)
Paul Tudor Jones 87,100 sh (-30.82%)
» More
Q2 2016

PDLI Guru Trades in Q2 2016

Jeremy Grantham 2,853,102 sh (+16.12%)
First Eagle Investment 2,800 sh (unchged)
Paul Tudor Jones Sold Out
Barrow, Hanley, Mewhinney & Strauss 297,175 sh (-0.36%)
Jim Simons 12,565,654 sh (-1.25%)
Joel Greenblatt 2,293,523 sh (-38.56%)
» More
Q3 2016

PDLI Guru Trades in Q3 2016

Paul Tudor Jones 90,300 sh (New)
Jim Simons 13,472,854 sh (+7.22%)
Barrow, Hanley, Mewhinney & Strauss 299,285 sh (+0.71%)
First Eagle Investment 2,800 sh (unchged)
Jeremy Grantham 2,295,234 sh (-19.55%)
Joel Greenblatt 1,266,121 sh (-44.80%)
» More
Q4 2016

PDLI Guru Trades in Q4 2016

Paul Tudor Jones 292,400 sh (+223.81%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 297,626 sh (-0.55%)
Jim Simons 12,875,700 sh (-4.43%)
Jeremy Grantham 1,070,509 sh (-53.36%)
Joel Greenblatt 29,531 sh (-97.67%)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:CRIS, NAS:FOMX, NAS:BSTC, NAS:BLCM, OTCPK:RCAR, NAS:ADXS, NAS:MCRB, NAS:PRTK, NAS:BOLD, NAS:MRUS, NAS:GERN, NAS:ARNA, NAS:AGEN, NAS:CRBP, NAS:TRVN, NAS:XBIT, NAS:AKBA, NAS:CLDX, NAS:RXDX, NAS:MYOK » details
Traded in other countries:PDL.Germany,
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer & immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets & maximizing value of its patent.

PDL BioPharma Inc was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies. It's U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri and Actemra. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company's licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.

Top Ranked Articles about PDL BioPharma Inc

Undervalued Companies With Growing EPS Atwood Oceanics and NeuStar have a wide margin of safety
Companies with growing EPS are often a good investment as they can return a very good profit to investors. Here is a selection of the most undervalued companies according to the DCF calculator that have a five-year growing EPS. Read more...

Ratios

vs
industry
vs
history
PE Ratio 2.09
PDLI's PE Ratio is ranked higher than
95% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. PDLI: 2.09 )
Ranked among companies with meaningful PE Ratio only.
PDLI' s PE Ratio Range Over the Past 10 Years
Min: 1.46  Med: 5.22 Max: 120
Current: 2.09
1.46
120
Forward PE Ratio 10.47
PDLI's Forward PE Ratio is ranked higher than
83% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. PDLI: 10.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 2.09
PDLI's PE Ratio without NRI is ranked higher than
95% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. PDLI: 2.09 )
Ranked among companies with meaningful PE Ratio without NRI only.
PDLI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.46  Med: 5.08 Max: 166.57
Current: 2.09
1.46
166.57
Price-to-Owner-Earnings 1.99
PDLI's Price-to-Owner-Earnings is ranked higher than
96% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. PDLI: 1.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PDLI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.33  Med: 5.73 Max: 70.2
Current: 1.99
1.33
70.2
PB Ratio 0.48
PDLI's PB Ratio is ranked higher than
98% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. PDLI: 0.48 )
Ranked among companies with meaningful PB Ratio only.
PDLI' s PB Ratio Range Over the Past 10 Years
Min: 0.44  Med: 3 Max: 38.99
Current: 0.48
0.44
38.99
PS Ratio 1.02
PDLI's PS Ratio is ranked higher than
95% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. PDLI: 1.02 )
Ranked among companies with meaningful PS Ratio only.
PDLI' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.06 Max: 12.64
Current: 1.02
0.82
12.64
Price-to-Free-Cash-Flow 2.33
PDLI's Price-to-Free-Cash-Flow is ranked higher than
98% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. PDLI: 2.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PDLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.42 Max: 333.14
Current: 2.33
1.51
333.14
Price-to-Operating-Cash-Flow 2.33
PDLI's Price-to-Operating-Cash-Flow is ranked higher than
98% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. PDLI: 2.33 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PDLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.92 Max: 57.58
Current: 2.33
1.51
57.58
EV-to-EBIT 1.37
PDLI's EV-to-EBIT is ranked higher than
83% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. PDLI: 1.37 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.8  Med: 3.9 Max: 147.7
Current: 1.37
0.8
147.7
EV-to-EBITDA 1.34
PDLI's EV-to-EBITDA is ranked higher than
84% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. PDLI: 1.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.8  Med: 3.8 Max: 32.2
Current: 1.34
0.8
32.2
PEG Ratio 0.09
PDLI's PEG Ratio is ranked higher than
99% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. PDLI: 0.09 )
Ranked among companies with meaningful PEG Ratio only.
PDLI' s PEG Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.24 Max: 4.81
Current: 0.09
0.06
4.81
Shiller PE Ratio 2.21
PDLI's Shiller PE Ratio is ranked higher than
91% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. PDLI: 2.21 )
Ranked among companies with meaningful Shiller PE Ratio only.
PDLI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.99  Med: 10.63 Max: 167.4
Current: 2.21
1.99
167.4
Current Ratio 2.92
PDLI's Current Ratio is ranked lower than
64% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PDLI: 2.92 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.89 Max: 76.07
Current: 2.92
0.26
76.07
Quick Ratio 2.91
PDLI's Quick Ratio is ranked lower than
61% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. PDLI: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.82 Max: 76.07
Current: 2.91
0.26
76.07
Days Sales Outstanding 26.70
PDLI's Days Sales Outstanding is ranked higher than
77% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PDLI: 26.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.19  Med: 0.9 Max: 36.59
Current: 26.7
0.19
36.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.50
PDLI's Dividend Yield % is ranked higher than
91% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. PDLI: 4.50 )
Ranked among companies with meaningful Dividend Yield % only.
PDLI' s Dividend Yield % Range Over the Past 10 Years
Min: 2.26  Med: 8.12 Max: 20.55
Current: 4.5
2.26
20.55
Dividend Payout Ratio 0.24
PDLI's Dividend Payout Ratio is ranked higher than
66% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. PDLI: 0.24 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PDLI' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.36 Max: 0.52
Current: 0.24
0.24
0.52
Forward Dividend Yield % 8.93
PDLI's Forward Dividend Yield % is ranked higher than
97% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. PDLI: 8.93 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.50
PDLI's 5-Year Yield-on-Cost % is ranked higher than
78% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. PDLI: 4.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PDLI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.26  Med: 8.12 Max: 20.55
Current: 4.5
2.26
20.55
3-Year Average Share Buyback Ratio -5.50
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. PDLI: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -5.4 Max: -0.1
Current: -5.5
-7.9
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 3.26
PDLI's Price-to-Tangible-Book is ranked higher than
60% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PDLI: 3.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86  Med: 3.69 Max: 47.78
Current: 3.26
0.86
47.78
Price-to-Intrinsic-Value-Projected-FCF 0.13
PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. PDLI: 0.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.13  Med: 1.52 Max: 90.82
Current: 0.13
0.13
90.82
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.20
PDLI's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
95% of the 21 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PDLI: 0.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.33
PDLI's Price-to-Median-PS-Value is ranked higher than
88% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. PDLI: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 2.84 Max: 29.96
Current: 0.33
0.32
29.96
Price-to-Peter-Lynch-Fair-Value 0.24
PDLI's Price-to-Peter-Lynch-Fair-Value is ranked higher than
99% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. PDLI: 0.24 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PDLI' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.32 Max: 2.65
Current: 0.24
0.08
2.65
Price-to-Graham-Number 0.55
PDLI's Price-to-Graham-Number is ranked higher than
93% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. PDLI: 0.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PDLI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.34  Med: 2.13 Max: 14.85
Current: 0.55
0.34
14.85
Earnings Yield (Greenblatt) % 73.31
PDLI's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. PDLI: 73.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 25.7 Max: 119.5
Current: 73.31
0.7
119.5
Forward Rate of Return (Yacktman) % 73.88
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. PDLI: 73.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 5.4 Max: 83.1
Current: 73.88
-8.7
83.1

More Statistics

Revenue (TTM) (Mil) $355.9
EPS (TTM) $ 1.06
Beta0.61
Short Percentage of Float8.41%
52-Week Range $1.93 - 3.84
Shares Outstanding (Mil)165.54

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 226 186 187 210
EPS ($) 0.61 0.21 0.17 0.29
EPS without NRI ($) 0.61 0.21 0.17 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.10
» More Articles for NAS:PDLI

Headlines

Articles On GuruFocus.com
8 High-Yield Stocks With Falling Prices Feb 21 2017 
Medical Companies Offer Good Value Opportunities Sep 16 2016 
Undervalued Companies With Growing EPS Apr 04 2016 
Cash is Flowing Nicely for These Five Stocks Aug 19 2015 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Weekly 3-Year Low Highlights: APOL, PDLI, TC, ALLT, ELRC May 17 2015 
Hot Picks with High Yields Jul 23 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
My 4 Favorites From The 20 Cheapest Healthcare Dividend Stock List May 02 2013 
68 Top-Yielding Stocks with Ex-Dividend Date in March 2013 Feb 27 2013 

More From Other Websites
PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017 Feb 22 2017
8 High-Yield Stocks With Falling Prices Feb 21 2017
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 21 2017
PDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 17 2017
9 Top Pharmaceutical Stocks to Buy for the Dividends Feb 15 2017
PDL BioPharma Inc. Review of 3Q 2016 Results and Forward Outlook Jan 31 2017
LENSAR® Launches Streamline™ III to Assist Cataract Surgeons in Managing and Improving... Jan 26 2017
ETFs with exposure to PDL BioPharma, Inc. : January 20, 2017 Jan 20 2017
Can PDL BioPharma Be a Top Choice for Value Investors? Jan 19 2017
PDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 09 2017
PDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Dec 20 2016
[$$] Medical-Device Company Enters Chapter 11 Dec 19 2016
ETFs with exposure to PDL BioPharma, Inc. : December 19, 2016 Dec 19 2016
LENSAR® Strategic Restructure in Partnership with PDL BioPharma, Inc. Dec 19 2016
PDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 16 2016
Is Vera Bradley, Inc. (VRA) Worthy of Your Portfolio? Dec 12 2016
Pace Holdings Corp (PACE): Hedge Fund Sentiment Unchanged Dec 08 2016
ETFs with exposure to PDL BioPharma, Inc. : December 5, 2016 Dec 05 2016
Is PDL BioPharma Inc (PDLI) Going to Burn These Hedge Funds? Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)